近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Tang H., Liang, YAnders RA, Taube JM, Qiu X, Mulgaonkar A Liu X, Harrington SM, Guo J Xin YXiong Y Nham K, Silvers W, Hao G, Sun X, Mingyi Chen, Hannan R Qiao J, Dong H, Peng H, and Fu YX. PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression.J. Clin Invest.2018, 128(2):580-588.
Yuzhu Hou, Hua Liang,Liufu Deng, Wenxin Zheng, Enyu Rao, Xiaona Huang, Helena Mauceri, Meng Xu, Ralph R. Weichselbaum and Yang-Xin Fu. Non-canonical NF-κB antagonizes STING mediated DNA sensing in radiotherapy.Immunity.49(3):490-503. 2018
Han Y, Dong H, Peng H, Fu Y. Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance.Nat Commun.2018 Nov 2;9(1):4586. doi: 10.1038/s41467-018- 06890-y.
Qiao J, Liu Z, Dong C, Luan Y, Zhang A, Moore C, Fu K, Peng J, Wang Y, Ren Z, Han C, Xu T, Fu YX.Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+T Cell Apoptosis.Cancer Cell.2019;35(6):901-915.
Sun Z, Ren Z, Yang K, Liu Z, Cao S, Deng S, Xu L, Liang Y, Guo J, Bian Y, Xu H, Shi J, Wang F, Fu YX, Peng H.A next generation tumor-targeting IL-2 preferentially promotes tumor infiltrating CD8 +T cells response and effective tumor control.Nature Communication.2019 Aug 28;10(1):3874. PMC7113269.
Liu Z, Han C, Dong C, Shen A, Hsu E, Ren Z, Lu C, Liu L, Zhang A, Timmerman C, Pu Y, Wang Y, Chen M, Qiao J, Fu YX.Hypo-fractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Science Immunology.2019 Aug 9;4(38). pii: eaav6473
Han C, Liu Z, Zhang Y, Shen A, Dong C, Zhang A, Moore C, Ren Z, Lu C, Cao X, Zhang CL, Qiao J, Fu YX. Tumor Cells Suppress Radiation-Induced Immunity by Hijacking Caspase 9 Signaling.Nat Immunol. 2020, .21(5):546-554. PMID: 32231300.
Liu Z, Fu YX.Chemotherapy Induces Cancer-Fighting B Cells.Cell.2020 Mar 19;180(6):1037-1039.
Shi Y, Zheng W, Yang K, Harris KG, Ni K, Xue L, Lin W, Chang EB, Weichselbaum RR, Fu YX.Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling.J Exp Med.2020 217(5):e20192282.
Mender I, Zhang A, Ren Z, Han C, Deng Y, Siteni S, Li H, Zhu J, Vemula A, Shay JW,Fu YX.Telomere Stress Potentiates Host STINT Dependent Anti-Tumor Immunity.Cancer Cell.2020 S1535-6108(20)30270-1.
Lu C, Guan J, Lu S, Jin Q, Rousseau B, Lu T, Stephens D, Zhang H, Zhu J, Yang M, Ren Z, Liang Y, Liu Z, Han C, Liu L, Cao X, Zhang A, Qiao J, Batten K, Chen M, Castrillon DH, Wang T, Li B, Diaz LA Jr, Li GM, Fu YX.DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity.Cancer Cell.202039(1):96-108.
Guan J, Lu C, Jin Q, Lu H, Chen X, Tian L, Zhang Y, Ortega J, Zhang J, Siteni S, Chen M, Gu L, Shay JW, Davis AJ, Chen ZJ, Fu YX, Li GM. MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway.Cancer Cell.202039(1):109-121
Han C, Godfrey V, Liu Z, Han Y, Liu L, Peng H, Weichselbaum RR, Zaki H, Fu YX. The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation.Sci Immunol.2021, 6(59):eabc6998.
Hsu EJ, Cao X, Moon B, Bae J, Sun Z, Liu Z, Fu YX. A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy.Nat Commun.2021, 12(1):2768.
Zhang A, Ren Z, Tseng KF, Liu X, Li H, Lu C, Cai Y, Minna JD, Fu YX. Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors.Sci Transl Med.2021 Aug 4;13(605):eabg8693.
Guo J, Liang Y, Xue D, Shen J, Cai Y, Zhu J, Fu YX, Peng H. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity.Cell Res.2021 Aug 10. doi: 10.1038/s41422-021-00543-4.
Cao X, Liang Y, Hu Z, Li H, Yang J, Hsu EJ, Zhu J, Zhou J, Fu YX.Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nat Commun. 2021 Oct 7;12(1):5866. doi: 10.1038/s41467-021-26112-2.
Liu L, Chen J, Bae J, Li H, Sun Z, Moore C, Hsu E, Han C, Qiao J, Fu YX. Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells.Nat Biomed Eng. 2021 5(11):1261-1273. doi: 10.1038/s41551-021-00800-2.
Xue D, Moon B, Liao J, Guo J, Zou Z, Han Y, Cao S, Wang Y, Fu YX, Peng H. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors.Sci Immunol2022 Jan 7;7(67):eabi6899。
Ren Z, Zhang A, Sun Z, Liang Y, Ye J, Qiao J, Li B, Fu YX. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity.J Clin Invest.2022 Feb 1;132(3):e153604. DOI: 10.1172/JCI153604
京公网安备 11010802027423号